Click here to view the original post by Healio Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary to age-related macular degeneration.
According to a press release from Complement Therapeutics, CTx001, an adeno-associated virus-based therapy, is designed to treat GA by delivering a truncated version of complement receptor 1, with the aim of yielding “long-term potent modulation of the classical and alternative pathways of the complement cascade.”
The FDA grants fast track designation to expedite the development and review of therapies that treat serious conditions